Aarti Pharmalabs Share Price

NSE
AARTIPHARM •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Aarti Pharmalabs
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
12.8
TTM PE Ratio
Below industry Median
26.8
Price to Book Ratio
Above industry Median
3.6
Dividend yield 1yr %
Below industry Median
0.5
TTM PEG Ratio
PEG TTM is less than 1
1

Aarti Pharmalabs Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Aarti Pharmalabs Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
537.78 Cr
458.03 Cr
555.49 Cr
505.77 Cr
448.69 Cr

Aarti Pharmalabs Yearly Revenue

Mar 2024Mar 2023Mar 2022
1857.5 Cr
1947.55 Cr
1202.46 Cr

Aarti Pharmalabs Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
73.99 Cr
54.62 Cr
55.45 Cr
65.25 Cr
52.76 Cr

Aarti Pharmalabs Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022
216.9 Cr
193.49 Cr
122.25 Cr
Aarti Pharmalabs Result Highlights
  • Aarti Pharmalabs Ltd reported a 17.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.6%.

  • Its expenses for the quarter were up by 13.2% QoQ and 17.5% YoY.

  • The net profit increased 35.5% QoQ and increased 40.2% YoY.

  • The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 8.2 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Aarti Pharmalabs shareholding Pattern

Promoter
44.7%
Foreign Institutions
8.6%
Mutual Funds
3.9%
Domestic Institutions
10.4%
Public
36.3%
Promoter
46.1%
Foreign Institutions
7.4%
Mutual Funds
4.9%
Domestic Institutions
11.3%
Public
35.2%
Promoter
46.5%
Foreign Institutions
7.1%
Mutual Funds
4.7%
Domestic Institutions
11.5%
Public
35%
Promoter
46.5%
Foreign Institutions
8.3%
Mutual Funds
2.7%
Domestic Institutions
10%
Public
35.2%
Promoter
46.5%
Foreign Institutions
8.2%
Mutual Funds
2%
Domestic Institutions
9.9%
Public
35.4%
Promoter
46.3%
Foreign Institutions
8.4%
Mutual Funds
2.7%
Domestic Institutions
10.6%
Public
34.7%

Aarti Pharmalabs Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
5
5Day EMA
775.30
10Day EMA
754.80
12Day EMA
746.20
20Day EMA
719.20
26Day EMA
705.80
50Day EMA
677.70
100Day EMA
654.30
200Day EMA
618.70
5Day SMA
790.60
10Day SMA
760.60
20Day SMA
690.50
30Day SMA
675.80
50Day SMA
660.60
100Day SMA
644.70
150Day SMA
642.00
200Day SMA
631.90
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
213845 Rs
761442 Rs
Week Rs
403982 Rs
1224689 Rs
Month Rs
422305 Rs
1382826 Rs
Resistance & Support
774.22
Pivot
Resistance
First Resistance
794.03
Second Resistance
823.72
Third Resistance
843.53
Support
First Support
744.53
Second support
724.72
Third Support
695.03
Relative Strength Index
62.21
Money Flow Index
90.68
MACD
40.37
MACD Signal
30.41
Average True Range
42.41
Average Directional Index
35.60
Rate of Change (21)
23.02
Rate of Change (125)
16.63

Aarti Pharmalabs Company background

Founded in: 2019
Managing director: Narendra Jagannath Salvi
Aarti Pharmachem Limited was incorporated as a Public Limited Company in 2019. The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives situated in India.In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005 commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022.The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021. Pursuant to the said Demerger Scheme, Aarti Industries Limited hived off its Pharmaceutical Division into a separate entity Aarti Pharmalabs Limited and accordingly, all the assets and liabilities pertaining to the Pharma Business Undertaking got transferred and vested into the Company effective from the above said Date.Thereafter, the Company in 2023 commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023.9,06,26,008 Equity Shares of Rs 5/ each got listed effective January 30, 2023.
Read More

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹736.8 in NSE and ₹757.2 in BSE as on 21/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Aarti Pharmalabs share price in the past 1-year return was 42.94. The Aarti Pharmalabs share hit a 1-year low of Rs. 399.55 and a 1-year high of Rs. 837.25.

The market cap of Aarti Pharmalabs is Rs. 6927 Cr. as of 21/2/2025 12:00:00 AM.

The PE ratios of Aarti Pharmalabs is 29.9 as of 21/2/2025 12:00:00 AM.

The PB ratios of Aarti Pharmalabs is 4.05 as of 21/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Aarti Pharmalabs was 3.93% at the end of 21/2/2025 12:00:00 AM.

You can easily buy Aarti Pharmalabs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -